Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's disease

Hu, Kaili; Shi, Yanbin; Jiang, Wenming; Han, Jiaying; Huang, Shixian; Jiang, Xinguo

doi:10.1016/j.ijpharm.2011.05.062

Cited by 216 publications

(114 citation statements)

References 42 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…Hu et al [30] This group also explored the intranasal drug delivery. For this purpose, PEG-PLGA NP were conjugated to odorranalectin (Ol-NP) to improve nose-to-brain drug delivery [31].…”

Section: Factor Deliverymentioning

confidence: 99%

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

2013

View full text Add to dashboard Cite

Current treatments for Parkinson's disease (PD) are aimed at addressing motor symptoms but there is no therapy focused on modifying the course of the disease.Successful treatment strategies have been so far limited and brain drug delivery remains a major challenge that restricts its treatment. This review provides an overview of the most promising emerging agents in the field of PD drug discovery, discussing improvements that have been made in brain drug delivery for PD. It will be shown that new approaches able to extend the length of the treatment, to release the drug in a continuous manner or to cross the blood brain barrier and target a specific region are still needed.Overall, the results reviewed here show that there is an urgent need to develop both symptomatic and disease-modifying treatments, giving priority to neuroprotective treatments. Promising perspectives are being provided in this field by rasagiline and by neurotrophic factors like glial cell line-derived neurotrophic factor. The identification of disease-relevant genes has also encouraged the search for disease-modifying therapies that function by identifying molecularly-targeted drugs. The advent of new molecular and cellular targets like α-synuclein, leucine-rich repeat serine/threonine protein kinase 2 or parkin, among others, will require innovative delivery therapies. In this regard, drug delivery systems (DDS) have shown great potential for improving the efficacy of conventional and new PD therapy and reducing its side effects. The new DDS discussed here, which include microparticles, nanoparticles and hydrogels among others, will probably open up possibilities that extend beyond symptomatic relief. However, further work needs to be done before DDS become a therapeutic option for PD patients.

show abstract

“…Hu et al [30] This group also explored the intranasal drug delivery. For this purpose, PEG-PLGA NP were conjugated to odorranalectin (Ol-NP) to improve nose-to-brain drug delivery [31].…”

Section: Factor Deliverymentioning

confidence: 99%

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

2013

View full text Add to dashboard Cite

show abstract

“…Different cells including MDCK cells [17,20,24,29] , BCECs [19,26,33,40] , bEnd.3 cells [28,39] , and glioma cells [20,34,37,41] were used as in vitro cell models treated at doses ranging from 10 to 15,000 μ g/ml. Small size, positively charged and less hydrophilic NPs were associated with enhanced cellular uptake [17] .…”

Section: Uptake Efficiencymentioning

confidence: 99%

“…The endocytosis process was proven by changing the temperature-, concentration-and time-dependent uptake and co-incubating cells with free targeting ligand and NaN 3 , which stops energy-dependent processes indicating an active endocytosis process [33,39] . Furthermore, the uptake mechanisms of different ligand-conjugated NPs were studied with cells preincubated with inhibitors.…”

Section: Uptake Efficiencymentioning

confidence: 99%

“…Furthermore, the uptake mechanisms of different ligand-conjugated NPs were studied with cells preincubated with inhibitors. By using chlorpromazine which inhibits clathrin-dependent and caveolae-dependent pathways, colchicines which inhibit the macropinocytosis pathway, and Brefeldin A (BFA) which inhibits the Golgi apparatus and lysosomerelated endocytosis process, transport of Lf-TPGS-PLA NPs (120 nm) across the membrane was demonstrated to be clathrin-mediated endocytosis [39] . The mechanism of uptake of Tf-PLGA NPs (90 nm) was confirmed as caveolae-dependent by co-incubating cells with filipin, a caveolae inhibitor, and other different types of inhibitors.…”

Section: Uptake Efficiencymentioning

confidence: 99%

“…Among 29 papers cited in this review, 9 papers performed in vitro studies [20,23,24,31,33,37,38,40] , 8 papers focused on in vivo studies [13,15,16,18,21,25,27,30] , and 12 papers did both in vitro and in vivo studies [14,17,19,22,26,28,29,32,34,35,39,41] .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier

Sabliov

2013

Nanotechnology Reviews

View full text Add to dashboard Cite

Abstract:The blood-brain barrier (BBB), which protects the central nervous system (CNS) from unnecessary substances, is a challenging obstacle in the treatment of CNS disease. Many therapeutic agents such as hydrophilic and macromolecular drugs cannot overcome the BBB. One promising solution is the employment of polymeric nanoparticles (NPs) such as poly (lactic-co-glycolic acid) (PLGA) NPs as drug carrier. Over the past few years, significant breakthroughs have been made in developing suitable PLGA and poly (lactic acid) (PLA) NPs for drug delivery across the BBB. Recent advances on PLGA/PLA NPs enhanced neural delivery of drugs are reviewed in this paper. Both in vitro and in vivo studies are included. In these papers, enhanced cellular uptake and therapeutic efficacy of drugs delivered with modified PLGA/PLA NPs compared with free drugs or drugs delivered by unmodified PLGA/ PLA NPs were shown; no significant in vitro cytotoxicity was observed for PLGA/PLA NPs. Surface modification of PLGA/PLA NPs by coating with surfactants/polymers or covalently conjugating the NPs with targeting ligands has been confirmed to enhance drug delivery across the BBB. Most unmodified PLGA NPs showed low brain uptake ( < 1 % ), which indirectly confirms the safety of PLGA/PLA NPs used for other purposes than treating CNS diseases.

show abstract

The Role of Biomedical Nanotechnology in CNS and Neurological Disorders

2022

Nanoparticles for Therapeutic Applications

View full text Add to dashboard Cite

Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's disease

Cited by 216 publications

References 42 publications

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

PLA/PLGA nanoparticles for delivery of drugs across the blood-brain barrier

The Role of Biomedical Nanotechnology in CNS and Neurological Disorders

Contact Info

Product

Resources

About